Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInt.biotech. Regulatory News (IBT)

Share Price Information for Int.biotech. (IBT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 642.00
Bid: 638.00
Ask: 646.00
Change: 10.00 (1.58%)
Spread: 8.00 (1.254%)
Open: 636.00
High: 642.00
Low: 636.00
Prev. Close: 632.00
IBT Live PriceLast checked at -
International Biotechnology is an Investment Trust

To achieve capital growth through investing in high growth, development stage biotechnology companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM

15 Dec 2020 16:54

RNS Number : 7640I
Intl. Biotechnology Trust PLC
15 December 2020
 

 

 

 

International Biotechnology Trust plc (the Company)

Announcement of Results of Annual General Meeting (AGM)

The Company gives notice that all resolutions proposed in the Notice of the Meeting were duly passed at the AGM held today. Voting was held via poll and the results are as follows:

 

FOR

(inc. Discretionary)

AGAINST

TOTAL

(For & Against)

WITHHELD*

Resolution

 

Votes Cast

%

Votes Cast

%

Votes Cast

Votes Cast

Ordinary Resolutions

 

 

 

 

 

 

1 - Report and Accounts

 

10,562,772

100.00%

0

0.00%

10,562,772

2,523

2 - Remuneration Policy

 

10,102,858

95.91%

430,305

4.09%

10,533,163

32,132

3 - Remuneration Report

 

10,506,494

99.77%

24,375

0.23%

10,530,869

34,426

4 - Dividend Policy

 

10,549,085

99.94%

6,263

0.06%

10,555,348

9,947

5 - Dr Véronique Bouchet

 

9,160,083

86.78%

1,396,032

13.22%

10,556,115

9,179

6 - Miss Kate Cornish-Bowden

 

10,545,760

99.87%

13,672

0.13%

10,559,432

5,863

7 - Mrs Caroline Gulliver

 

10,504,427

99.59%

43,306

0.41%

10,547,733

17,562

8 - Mr Jim Horsburgh

 

10,539,775

99.92%

7,957

0.08%

10,547,732

17,562

9 - Mr Patrick Magee

 

10,550,208

99.91%

9,224

0.09%

10,559,432

5,863

10 - Auditors

 

9,272,741

87.94%

1,271,723

12.06%

10,544,464

20,830

11 - Auditors' remuneration

 

10,543,438

99.97%

3,352

0.03%

10,546,790

18,505

12 - Allot Securities

 

10,541,971

99.92%

8,416

0.08%

10,550,387

14,908

13 - Allot Securities (additional)

 

10,492,190

99.46%

56,657

0.54%

10,548,847

16,448

Special Resolutions

 

 

 

 

 

 

14 - Disapplication of pre-emption rights

 

10,499,790

99.64%

37,540

0.36%

10,537,330

27,965

15 - Disapplication of pre-emption rights (additional)

 

8,144,318

77.28%

2,394,389

22.72%

10,538,707

26,587

16 - Market purchases

 

10,538,211

99.89%

11,810

0.11%

10,550,021

15,274

17 - 14 clear days' notice

 

10,526,276

99.65%

36,861

0.35%

10,563,137

2,158

* Votes withheld are not a vote in law and are therefore not counted in the calculation of the percentages of the votes cast for and against a resolution.

 

 

The Board confirms that there was a significant proportion of proxy votes cast against resolution 15 (22.72%). The Board is aware that when combined the authorities sought under resolutions 14 and 15 to dis-apply statutory pre-emption rights amount to 20% of the Company's issued Ordinary Share capital which is higher than the level recommended by best practice in accordance with The Investment Association Share Capital Management Guidelines and the Pre-emption Group's Statement of Principles on Dis-applying Pre-emption Rights. However, the Board notes that the Prospectus Regulation allows for issuance for up to 20% of the Company's issued Ordinary Share capital without the need for a prospectus and therefore believes that the increased authority is justified and it would be in the best interest of Shareholders to provide the extra flexibility to issue further shares. The increased authority would avoid the additional delay and expense of a further Shareholder resolution, which would be required, in the event that the initial 10% authority is granted and exhausted.

 

Issuance is led by market demand and the Company's issuance strategy is to ensure that Shareholders are not forced to pay an excessive premium. New shares are issued at a small premium to NAV per share to ensure there is no asset dilution for our existing Shareholders. The increased size of the Company should improve liquidity and spread the operating costs across a greater number of Shareholders.

 

We are aware Institutional Shareholder Services, Inc had recommended Shareholders oppose the resolution given it is higher than the recommended level set by the Investment Association Share Capital Management Guidelines and the Pre-emption Group's Statement of Principles on Dis-applying Pre-emption Rights. However, we note that ISS has published updates to its UK proxy voting guidelines for 2021, aligning its policy with the position set out in the Pre-Emption Group guidelines such that the current 10% limit for dis-applying pre-emption rights when shares are to be issued at a premium has been removed. The Board will consider the level of authority to be sought at next years AGM in light of prevailing ISS and other governance guidance and will offer a meeting with those larger Shareholders who voted against.

A copy of all resolutions passed as special resolutions has been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

Gemma Metson

BNP Paribas Secretarial Services Limited

Company Secretary

Telephone: 020 7410 5971

 

 

15 DECEMBER 2020 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGFFEFMIESSEIE
Date   Source Headline
3rd May 202410:54 amRNSNet Asset Value(s)
2nd May 20244:57 pmRNSTransaction in Own Shares
2nd May 202410:33 amRNSNet Asset Value(s)
1st May 20244:15 pmRNSTransaction in Own Shares
1st May 202410:38 amRNSNet Asset Value(s)
30th Apr 20245:10 pmRNSTotal Voting Rights
30th Apr 20244:22 pmRNSTransaction in Own Shares
30th Apr 202410:18 amRNSNet Asset Value(s)
29th Apr 20244:57 pmRNSTransaction in Own Shares
29th Apr 202410:21 amRNSNet Asset Value(s)
29th Apr 20247:00 amRNSLatest Factsheet and Blog
26th Apr 202410:43 amRNSNet Asset Value(s)
25th Apr 20244:17 pmRNSTransaction in Own Shares
25th Apr 202410:41 amRNSNet Asset Value(s)
24th Apr 20245:32 pmRNSTransaction in Own Shares
24th Apr 202410:24 amRNSNet Asset Value(s)
23rd Apr 20243:40 pmRNSTransaction in Own Shares
23rd Apr 202411:04 amRNSNet Asset Value(s)
22nd Apr 20244:29 pmRNSTransaction in Own Shares
22nd Apr 202410:32 amRNSNet Asset Value(s)
19th Apr 20245:10 pmRNSTransaction in Own Shares
19th Apr 202410:12 amRNSNet Asset Value(s)
18th Apr 20245:06 pmRNSTransaction in Own Shares
18th Apr 202410:17 amRNSNet Asset Value(s)
17th Apr 20243:35 pmRNSTransaction in Own Shares
17th Apr 202410:35 amRNSNet Asset Value(s)
16th Apr 20245:33 pmRNSTransaction in Own Shares
16th Apr 202410:33 amRNSNet Asset Value(s)
15th Apr 20244:23 pmRNSTransaction in Own Shares
15th Apr 202411:33 amRNSNet Asset Value(s)
12th Apr 20244:29 pmRNSTransaction in Own Shares
12th Apr 202410:48 amRNSNet Asset Value(s)
11th Apr 20243:48 pmRNSTransaction in Own Shares
11th Apr 202410:25 amRNSNet Asset Value(s)
10th Apr 20245:17 pmRNSTransaction in Own Shares
10th Apr 202410:22 amRNSNet Asset Value(s)
9th Apr 20245:16 pmRNSTransaction in Own Shares
9th Apr 202411:03 amRNSNet Asset Value(s)
8th Apr 20244:42 pmRNSTransaction in Own Shares
8th Apr 202411:17 amRNSNet Asset Value(s)
5th Apr 202411:20 amRNSCompliance with Market Abuse Regulations
5th Apr 202410:22 amRNSNet Asset Value(s)
4th Apr 20244:51 pmRNSTransaction in Own Shares
4th Apr 202410:55 amRNSNet Asset Value(s)
3rd Apr 20245:14 pmRNSTransaction in Own Shares
3rd Apr 202410:32 amRNSNet Asset Value(s)
2nd Apr 20244:08 pmRNSTransaction in Own Shares
2nd Apr 202411:09 amRNSNet Asset Value(s)
28th Mar 20245:15 pmRNSTotal Voting Rights
28th Mar 20245:05 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.